NEW YORK, NY / ACCESSWIRE / October 4, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Curaleaf Holdings, Inc. (“Curaleaf” or the Company”) (CURLF) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Curaleaf securities between November 21, 2018 and July 22, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm’s site:www.bgandg.com/curlf.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration (“FDA”); and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you wish to review a copy of the